- Home
- EXEL vs REGCO Comparison
EXEL vs REGCO Comparison
Compare EXEL & REGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | REGCO |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | 500 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | N/A |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | REGCO |
|---|---|---|
| Price | $41.94 | $22.30 |
| Analyst Decision | Buy | |
| Analyst Count | 24 | 0 |
| Target Price | ★ $45.18 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | N/A |
| Earning Date | 11-04-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.55 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,288,218,000.00 | N/A |
| Revenue This Year | $9.84 | N/A |
| Revenue Next Year | $11.92 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $31.90 | N/A |
| 52 Week High | $49.62 | N/A |
Technical Indicators
Market Signals| Indicator | EXEL | REGCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 34.93 |
| Support Level | $40.83 | $22.49 |
| Resistance Level | $42.09 | $22.96 |
| Average True Range (ATR) | 1.05 | 0.17 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 30.00 | 5.06 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About REGCO Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.